Tandem Diabetes Care (TNDM) Reports a Beat and Raise Ahead of Mobi Launch - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Steven Lichtman reiterated an Outperform rating and $142.00 price target on Tandem Diabetes Care (NASDAQ: TNDM) after reporting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
